Nuvectis Pharma, Inc. (NVCT) Key Metrics
NVCT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $607.2M
- Enterprise value
- $664.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 75.6 10-yr median 9.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.24
NVCT key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNVCT valuation Price multiples at each fiscal year-end price.
NVCT returns How much profit the business earns on the capital it uses.
NVCT per-share figures Results divided by the shares outstanding at year-end.
NVCT financial health Debt, liquidity and how easily interest is covered.
NVCT valuation history
NVCT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NVCT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NVCT price vs earnings per share
NVCT key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $164.7M | $92.6M | $129.7M | $94.9M | — | — |
| Enterprise value | $133.1M | $74.0M | $110.6M | $74.9M | — | — |
| Price / sales | — | — | — | 637.1 | — | — |
| Price / book | 8.9 | 9.5 | 10.6 | 6.7 | — | — |
| EV / sales | — | — | — | 502.9 | — | — |
| Earnings yield | −16.1% | −20.5% | −17.2% | −19.8% | — | — |
| Free cash flow yield | −9.7% | −13.2% | −12.3% | −14.3% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | — | — |
| Share price at fiscal year-end | $7.55 | $5.41 | $8.34 | $7.50 | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 |
| Earnings per share | −$1.21 | −$1.11 | −$1.43 | −$1.48 | −$1.01 | −$0.00 |
| Operating cash flow per share | −$0.73 | −$0.72 | −$1.03 | −$1.07 | −$0.75 | $0.00 |
| Free cash flow per share | −$0.73 | −$0.72 | −$1.03 | −$1.07 | −$0.75 | $0.00 |
| Cash per share | $1.45 | $1.08 | $1.23 | $1.58 | $0.45 | $0.45 |
| Book value per share | $0.84 | $0.57 | $0.78 | $1.12 | −$0.87 | −$0.00 |
| Tangible book value per share | $0.84 | $0.57 | $0.78 | $1.12 | −$0.87 | −$0.00 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares outstanding | 21.8M | 17.1M | 15.6M | 12.7M | 12.7M | 12.7M |
| Change in shares outstanding | +27.5% | +10.0% | +22.9% | −0.5% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −188.0% | −173.4% | −168.5% | — | — | — |
| Return on assets (ROA) | −105.1% | −100.6% | −112.5% | −138.8% | −193.6% | −0.2% |
| Return on tangible assets | −83.4% | −102.1% | −116.0% | −92.1% | −193.6% | −0.2% |
| Financial health | ||||||
| Cash & short-term investments | $31.6M | $18.5M | $19.1M | $20.0M | $5.7M | $5.7M |
| Net debt | −$31.6M | −$18.5M | −$19.1M | −$20.0M | −$5.7M | −$5.7M |
| Current ratio | 2.38 | 2.09 | 2.75 | 3.30 | 2.41 | 583.30 |
| Quick ratio | 2.38 | 2.09 | 2.75 | 3.30 | 2.41 | 583.30 |
| Interest coverage | — | — | — | -129.1 | — | — |
| Working capital | $18.4M | $9.7M | $12.2M | $14.2M | $3.4M | $5.8M |
| Invested capital | −$13.2M | −$8.8M | −$6.9M | −$5.8M | −$16.8M | −$5.8M |
| Tangible asset value | $18.4M | $9.7M | $12.2M | $14.2M | −$11.0M | $6.6M |
| Net current asset value | $18.4M | $9.7M | $12.2M | $14.2M | −$11.8M | $5.8M |
| Graham net-net per share | $0.84 | $0.56 | $0.78 | $1.09 | −$0.94 | $0.45 |
| Capital allocation | ||||||
| Share buybacks (net) | — | — | — | $0 | — | — |
| Capex / revenue | — | — | — | 0.0% | — | — |
| Capex / operating cash flow | — | — | — | — | — | 0.0% |
| Capex / depreciation | — | — | — | 0.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | — | — | — | 1,145.6% | — | — |
| R&D / revenue | — | — | — | 8,877.2% | — | — |
| SG&A / revenue | — | — | — | 4,031.5% | — | — |
| Efficiency | ||||||
| Days payables outstanding | — | — | 45.3 | 37.6 | 15.1 | — |
| Payables turnover | — | — | 8.06 | 9.69 | 24.15 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Average payables | $4.4M | $2.6M | $2.8M | $2.0M | $534,000 | $10,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from NVCT's annual financial statements (latest annual report filed February 11, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NVCT valuation and financial ratios
Nuvectis Pharma earned a return on equity of −188.0% in fiscal 2025. The share count rose 71.5% from 12.7M to 21.8M over 5 years.
See the NVCT income statement, the NVCT chart for price history, or the NVCT stock overview for the latest quote and news.
NVCT key metrics FAQ
What is Nuvectis Pharma's return on equity?
Nuvectis Pharma's return on equity (ROE) was −188.0% in fiscal 2025: net income of -$26.4 million on average shareholders' equity of $14.1 million.
What is Nuvectis Pharma's free cash flow yield?
Nuvectis Pharma generated -$16.0 million of free cash flow in fiscal 2025, a free cash flow yield of −9.7% on its market value at year-end ($164.7 million).
What is Nuvectis Pharma's current ratio?
Nuvectis Pharma's current ratio was 2.38 at the end of fiscal 2025: current assets were 2.38 times current liabilities.